Can Veracyte (VCYT) Stay Reasonable After A 145% Rally?
Veracyte’s share price has climbed sharply over the past year, yet the valuation checks are pulling in different directions. An intrinsic value estimate based on a Discounted Cash Flow (DCF) suggests the stock trades below that estimate, while market multiples lean expensive and the broader score is weak.
- Veracyte has returned 144.5% over the past year, which puts extra focus on whether recent gains already reflect the company’s prospects.
- Rising earnings estimates and growth plans in areas like minimal residual disease testing can support the valuation, but the rich market multiple leaves less room if those expectations are delayed or scaled back.
- The company scores 1 out of 6 on our valuation checks, which points to a stock that screens as undervalued on the DCF intrinsic value estimate but not as a straightforward bargain across other measures.
The issue now is whether Veracyte’s strong share price run and split valuation signals leave attractive upside, or mainly highlight the need for caution on what investors are paying for future growth.
Is Veracyte Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Veracyte’s future cash generation could be worth in today’s dollars. For Veracyte, the model is based on last twelve month free cash flow of about $153.3 million and assumes that cash flows continue growing from this base rather than shrinking or staying flat.
On these projections, the DCF model points to an intrinsic value of about $74 per share, implying the stock trades at roughly a 20.3% discount on this method. A recent upgrade to a Strong Buy rating linked to higher earnings estimates helps explain why the cash flow outlook embedded in the model is relatively constructive, even though the market price has already moved up sharply.
Overall, the DCF workup suggests Veracyte stock currently appears undervalued relative to its projected cash flows, based on these assumptions.
Our Discounted Cash Flow (DCF) analysis suggests Veracyte is undervalued by 20.3%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Does Veracyte Look Pricey on Earnings?
The P/E ratio is a useful yardstick for Veracyte because the focus is firmly on what investors are paying for each dollar of current earnings. Veracyte trades on a P/E of about 53.7x, only slightly above the peer average of around 51.8x but more than triple the broader biotech industry average of roughly 17.4x.
A fair P/E for Veracyte based on its profile is estimated at about 19.7x. This is well below where the stock currently changes hands. That gap suggests investors are paying a rich premium for the earnings outlook compared with what this model implies would be reasonable given the company’s risk and fundamentals.
On this P/E yardstick, Veracyte stock screens as overvalued relative to the level that would typically be suggested by its characteristics.
See what the numbers say about this price — find out in our valuation breakdown.
The Veracyte Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Veracyte pick up where this valuation split leaves off by spelling out the specific growth, margin and earnings paths that would need to play out for Veracyte's stock to be worth materially more or less than it is today, and they sit on the company's Community page. Rather than centering on a single model output or multiple, each one lays out the assumptions behind its view of fair value so you can compare them with actual results over time.
Veracyte’s community views split sharply, with one camp leaning into the cancer test growth story and the other focused on reimbursement and pricing pressure.
Bull case: 12% undervalued
"Analysts broadly agree that Decipher and Afirma are driving double-digit growth through increased adoption, but current projections may understate upside..."
Read the full Bull Case to see why Veracyte could be undervalued
Bear case: 60% overvalued
"As government and private insurers intensify reimbursement scrutiny and implement tighter controls on test approvals and pricing, Veracyte faces the prospect of stagnant or declining average selling prices and increased denials..."
Read the full Bear Case to see why Veracyte could be overvalued
Do you think there's more to the story for Veracyte? Head over to our Community to see what others are saying!
The Bottom Line
For Veracyte, the Discounted Cash Flow (DCF) intrinsic value estimate points to undervaluation, while the earnings multiple view flags the stock as overvalued, and the broader checks remain weak despite that DCF support. The gap comes down to what you trust more: the cash flow potential implied by current funding and investment plans, or the high P/E that already bakes in strong growth and sentiment versus peers. From here, the crux is whether Veracyte can deliver on the earnings and cash flow path that would make the current premium multiple, and any DCF discount, look justified rather than a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com